Grufity logoGrufity logo

Halozyme Therapeutics Inc Stock Research

HALO

34.49USD+0.81(+2.40%)Market Closed

Market Summary

USD34.49+0.81
Market Closed
2.40%

HALO Alerts

HALO Stock Price

HALO RSI Chart

HALO Valuation

Market Cap

4.7B

Price/Earnings (Trailing)

23.06

Price/Sales (Trailing)

7.06

EV/EBITDA

21.74

Price/Free Cashflow

19.81

HALO Price/Sales (Trailing)

HALO Profitability

EBT Margin

37.71%

Return on Equity

119.04%

Return on Assets

10.98%

Free Cashflow Yield

5.05%

HALO Fundamentals

HALO Revenue

Revenue (TTM)

660.1M

Revenue Y/Y

77.93%

Revenue Q/Q

-13.15%

HALO Earnings

Earnings (TTM)

202.1M

Earnings Y/Y

-13.58%

Earnings Q/Q

-6.38%

Price Action

52 Week Range

32.8359.46
(Low)(High)

Last 7 days

-4.4%

Last 30 days

-31.1%

Last 90 days

-40.0%

Trailing 12 Months

-10.9%

HALO Financial Health

Current Ratio

5.65

Debt/Equity

8.79

Debt/Cashflow

0.16

HALO Investor Care

Buy Backs (1Y)

1.70%

Diluted EPS (TTM)

1.44

Peers (Alternatives to Halozyme Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
127.1B
26.3B
0.79% 2.78%
19.4
4.83
1.32% 11.18%
99.8B
27.3B
-4.19% 39.66%
21.72
3.66
-0.09% -26.23%
58.1B
19.3B
-4.61% -16.03%
6.95
3.02
4.29% -31.47%
39.0B
10.2B
-0.92% 26.77%
12.8
3.83
-7.36% 95.80%
MID-CAP
9.4B
1.5B
-5.59% 3.19%
60.62
6.29
31.34% 72.43%
3.1B
108.5M
-21.66% -32.82%
-9.55
28.71
122.90% -12.19%
2.2B
107.9M
21.83% 38.60%
-4.63
20.79
54.84% 17.36%
2.2B
60.9M
-25.55% -48.21%
-7.49
35.56
17.51% 22.00%
SMALL-CAP
1.3B
112.0M
-7.70% -49.25%
-4.81
11.47
-70.76% -603.77%
1.1B
7.0M
-17.00% 22.02%
-7.14
159.78
131.81% -45.39%
524.4M
96.3M
-14.58% -86.07%
-1.86
5.45
72.44% -32.79%
519.7M
2.0B
-33.63% -92.58%
-0.79
0.26
72.89% 62.27%
276.9M
111.3M
-42.96% -71.96%
-1.44
2.49
0.54% -7.86%
101.6M
107.0K
-17.23% -85.52%
-0.94
949.93
-88.00% -52.91%
26.0M
-
40.00% -84.44%
-0.32
3.21
0.51% -185.61%

Financials for Halozyme Therapeutics

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue13.7%660581487472443
  S&GA Expenses20.1%14412098.0053.0050.00
  R&D Expenses23.0%67.0054.0046.0039.0036.00
Costs and Expenses18.6%393331246171167
EBITDA8.1%272252245305-
EBITDA Margin-5.0%0.41*0.43*0.50*0.65*-
Earnings Before Taxes6.9%249233233295249
EBT Margin-6.0%0.38*0.40*0.48*0.63*-
Interest Expenses17.4%17.0014.009.007.008.00
Net Income-4.3%202211366435403
Net Income Margin-15.8%0.31*0.36*0.75*0.92*-
Free Cahsflow-0.9%235238290287-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-1.2%1,8421,8651,7811,1621,104
  Current Assets13.1%739653542989926
    Cash Equivalents59.1%23414791.00118119
  Inventory-3.1%10010398.0048.0054.00
  Goodwill105.1%409199199--
  Current Liabilities19.6%131109200112117
  Long Term Debt30.1%1,4931,147788787-
    LT Debt, Current0.1%13.0013.0099.0090.0089.00
    LT Debt, Non Current89.4%1,491787---
Shareholder's Equity75.1%17097.00293260197
  Retained Earnings67.5%14386.0024.001.00-58.91
  Additional Paid-In Capital107.7%27.0013.00271262256
Accumulated Depreciation9.7%15.0014.0013.0013.00-
Shares Outstanding0.0%135135138138137
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations0.0%240240292289299
  Share Based Compensation9.4%24.0022.0021.0021.0021.00
Cashflow From Investing37.9%-487-784-800-410-406
Cashflow From Financing81.2%362200152-26078.00
  Buy Backs-25.0%20026786.00151-

Risks for HALO

What is the probability of a big loss on HALO?

78.8%


Probability that Halozyme Therapeutics stock will be more than 20% underwater in next one year

17.7%


Probability that Halozyme Therapeutics stock will be more than 30% underwater in next one year.

0.4%


Probability that Halozyme Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does HALO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Halozyme Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for HALO

Cumulative Returns on HALO

19.1%


10-Year Cumulative Returns

21.4%


7-Year Cumulative Returns

13.2%


5-Year Cumulative Returns

27.6%


3-Year Cumulative Returns

What are the long-term rolling returns for HALO?

FIve years rolling returns for Halozyme Therapeutics.

Annualized Returns

Which funds bought or sold HALO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
added
18.37
33,256,800
80,533,800
0.09%
2023-03-10
BAILLIE GIFFORD & CO
unchanged
-
13,415
43,415
-%
2023-03-08
SHEETS SMITH WEALTH MANAGEMENT
new
-
259,805
259,805
0.04%
2023-03-06
Rockefeller Capital Management L.P.
added
228
1,476,000
1,871,000
0.01%
2023-02-28
Voya Investment Management LLC
reduced
-6.39
3,916,680
15,203,700
0.02%
2023-02-24
SRS Capital Advisors, Inc.
reduced
-18.42
-236
1,764
-%
2023-02-24
NATIXIS
sold off
-100
-1,487,000
-
-%
2023-02-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
added
9.97
602,000
1,633,000
0.02%
2023-02-21
NORTHWESTERN MUTUAL INVESTMENT MANAGEMENT COMPANY, LLC
reduced
-37.12
-75,010
711,990
0.02%
2023-02-21
MACQUARIE GROUP LTD
added
1.97
47,174,000
148,239,000
0.17%

1–10 of 43

Latest Funds Activity

Are funds buying HALO calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own HALO
No. of Funds

Halozyme Therapeutics News

MarketBeat

Assenagon Asset Management S.A. Raises Stock Holdings in ....

MarketBeat,
2 days ago

Investor's Business Daily

PR Newswire

Schedule 13G FIlings of Halozyme Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 10, 2023
invesco ltd.
5.2%
7,036,951
SC 13G
Feb 10, 2023
blackrock inc.
14.2%
19,196,061
SC 13G/A
Feb 10, 2023
artisan partners limited partnership
5.3%
7,140,953
SC 13G/A
Feb 09, 2023
vanguard group inc
9.84%
13,303,847
SC 13G/A
Jan 26, 2023
blackrock inc.
13.6%
18,214,071
SC 13G/A
Jan 20, 2023
blackrock inc.
13.6%
18,214,071
SC 13G
Feb 04, 2022
artisan partners limited partnership
6.8%
9,505,768
SC 13G/A
Jan 28, 2022
blackrock inc.
13.8%
19,439,863
SC 13G/A
Feb 12, 2021
bb biotech ag
2.9%
3,970,000
SC 13G/A
Feb 10, 2021
artisan partners limited partnership
7.6%
10,284,136
SC 13G/A

HALO Fair Value

Halozyme Therapeutics fair value in different scenarios

The table shows the Fair Value estimates for Halozyme Therapeutics for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

51.42

49.09%

82.89

140.33%

243.75

606.73%

417.25

1109.77%

617.69

1690.92%
Current Inflation

47.09

36.53%

74.47

115.92%

212.88

517.22%

358.73

940.10%

526.84

1427.52%
Very High Inflation

41.74

21.02%

64.31

86.46%

176.68

412.26%

291.29

744.56%

423.03

1126.53%

Historical Halozyme Therapeutics Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Halozyme Therapeutics

View All Filings
Date Filed Form Type Document
Mar 24, 2023
ARS
ARS
Mar 24, 2023
DEF 14A
DEF 14A
Mar 24, 2023
DEFA14A
DEFA14A
Mar 16, 2023
8-K
Current Report
Mar 13, 2023
8-K
Current Report
Mar 09, 2023
4
Insider Trading
Mar 01, 2023
4
Insider Trading
Mar 01, 2023
4
Insider Trading
Feb 28, 2023
4
Insider Trading
Feb 23, 2023
8-K
Current Report

Latest Insider Trading transactions for HALO

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-09
Torley Helen
sold
-427,270
42.727
-10,000
president and ceo
2023-03-09
Torley Helen
acquired
146,600
14.66
10,000
president and ceo
2023-03-08
Torley Helen
sold
-432,590
43.259
-10,000
president and ceo
2023-03-08
Torley Helen
acquired
146,600
14.66
10,000
president and ceo
2023-03-07
Torley Helen
acquired
146,600
14.66
10,000
president and ceo
2023-03-07
Torley Helen
sold
-454,690
45.469
-10,000
president and ceo
2023-03-01
Torley Helen
gifted
-
-
-10,000
president and ceo
2023-03-01
Henderson Jeffrey William
sold
-477,100
47.71
-10,000
-
2023-02-28
Henderson Jeffrey William
sold
-485,100
48.51
-10,000
-
2023-02-27
LaBarre Michael J.
sold
-495,483
49.5483
-10,000
svp, chief technical officer

1–10 of 50

Helen I. Torley
140
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

HALO Income Statement

2022-12-31
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues:   
Total revenues$ 660,116$ 443,310$ 267,594
Operating expenses:   
Cost of sales139,30481,41343,367
Amortization of intangible assets43,14800
Research and development66,60735,67234,236
Selling, general and administrative143,52650,32345,736
Total operating expenses392,585167,408123,339
Operating income267,531275,902144,255
Other income (expense):   
Investment and other income, net1,0461,1025,425
Induced conversion expense related to convertible notes(2,712)(20,960)0
Interest expense(16,947)(7,526)(20,378)
Net income before income taxes248,918248,518129,302
Income tax expense (benefit)46,789(154,192)217
Net income$ 202,129$ 402,710$ 129,085
Net income per share:   
Basic (USD per share)$ 1.48$ 2.86$ 0.95
Diluted (USD per share)$ 1.44$ 2.74$ 0.91
Shares used in computing net income per share:   
Basic (shares)136,844140,646136,206
Diluted (shares)140,608146,796141,463
Royalties   
Revenues:   
Total revenues$ 360,475$ 203,900$ 88,596
Product sales, net   
Revenues:   
Total revenues191,030104,22455,987
Revenues under collaborative agreements   
Revenues:   
Total revenues$ 108,611$ 135,186$ 123,011

HALO Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 234,195$ 118,719
Marketable securities, available-for-sale128,599622,203
Accounts receivable, net and other contract assets231,07290,975
Inventories100,12353,908
Prepaid expenses and other current assets45,02440,482
Total current assets739,013926,287
Property and equipment, net75,5708,794
Prepaid expenses and other assets26,30113,414
Goodwill409,0490
Intangible assets, net546,6520
Deferred tax assets, net44,426155,434
Restricted cash500500
Total assets1,841,5111,104,429
Current liabilities:  
Accounts payable17,6931,541
Accrued expenses96,51624,441
Deferred revenue, current portion3,2461,746
Current portion of long-term debt, net13,33489,419
Total current liabilities130,789117,147
Deferred revenue, net of current portion2,2532,530
Long-term debt, net1,492,766787,255
Long-term debt, net30,433544
Contingent liability15,4720
Commitments and contingencies (Note 12)
Stockholders’ equity:  
Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding00
Common stock - $0.001 par value; 300,000 shares authorized; 135,154 and 137,498 shares issued and outstanding at December 31, 2022 and 2021, respectively135138
Additional paid-in capital27,368256,347
Accumulated other comprehensive loss(922)(620)
Retained earnings (Accumulated deficit)143,217(58,912)
Total stockholders’ equity169,798196,953
Total liabilities and stockholders’ equity$ 1,841,511$ 1,104,429